| ALS/PARKINSONISM
                        DEMENTIA COMPLEX | 
            
               
               | ALTERNATE NAMES | ALS-PDC; ALS/PDC Syndrome of Guam; Amyotrophic Lateral Sclerosis/Parkinsonism Dementia
                     Complex; Guam Disease; Kii ALS-PDC; Lytico-Bodig Motor Neuron Disease; Parkinsonism
                     Dementia-ALS Complex; PDALS
                   | 
            
               
               | DESCRIPTION | Amyotrophic
                        Lateral Sclerosis/Parkinsonisim Dementia Complex (ALS/PDC) is a rare malignant form of amyotrophic lateral sclerosis (ALS). ALS/PDC is an endemic
                     neurodegenerative disorder, known to occur primarily on the island of Guam and the
                     Kii peninsula of Japan. It is characteristic of classical ALS, parkinsonism, and dementia.
                     The cause of this disorder is widespread neurofibrillary degeneration in the brain
                     and spinal cord. This type of damage results in bradykinesia (abnormal slowness of
                     physical movement), rigidity, tremor, forgetfulness, and dementia.
                   | 
            
               
               | DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND
                        ICD-9-CM/ICD-10-CM
                        CODING | Diagnostic testing: There is no specific test or procedure to establish the diagnosis of ALS/PDC. ALS/PDC
                     diagnosis is based on history, neurological findings consistent with the diagnosis
                     of ALS/PDC.
                   Electrophysiological and neuroimaging testing is used to rule out other impairments
                     that may cause similar signs and symptoms. There are no definitive biomarkers that
                     clearly distinguish ALS/PDC from other degenerative neurological disorders.
                   Physical
                        findings: ICD-9: 331.0
                   ICD-10: F02
                   | 
            
               
               | PROGRESSION | The average onset of the disease is in the 40s. As the disease progresses, people
                     experience increasing cognitive deficits, spasticity, muscle atrophy, and weakness.
                     These symptoms progressively worsen to a vegetative state with death occurring within
                     4-6 years after diagnosis.
                   | 
            
               
               | TREATMENT | There is currently no cure for ALS/PDC. Treatment involves the management of symptoms. Management of symptoms may include: 
                     
                        
                           • 
                              Cholinesterase inhibitors for the treatment of neuropsychiatric symptoms;
                        
                           • 
                              Levodopa-carbidopa combinations to treat movement disorders;
                        
                           • 
                              Physical therapy for cardiovascular and skeletal muscle strengthening; flexibility,
                                 as well as for gait training; and
                              
                        
                           • 
                              Occupational therapy helps to maintain skills and promote function and independence. The primary bulbar muscles affected by this disorder include the pharynx, tongue,
                     and part of the larynx. Issues such as low voice volume, poor enunciation, poor bulbar
                     muscular strength, and swallowing difficulties are treated with speech therapy.
                   | 
            
               
               | SUGGESTED PROGRAMMATIC ASSESSMENT* | 
            
               
               | Suggested MER for Evaluation: 
                     
                        
                           • 
                              Clinical information from the claimant’s medical source(s) documenting a progressive
                                 physical, neurological finding of PD and ALS. Dementia is also critical and required
                                 for disability evaluation of ALS/PDC; and
                              
                        
                           • 
                              Activities of daily living report or a similar report completed by relative or caregiver. | 
            
               
               | Suggested Listings for Evaluation: | 
            
               
               | DETERMINATION | LISTING | REMARKS | 
            
               
               | Meets | 11.06 |   | 
            
               
               | 11.10 |   | 
            
               
               | 11.22 |   | 
            
               
               | 12.02 |   | 
            
               
               | Equals |   |   | 
            
               
               | *Adjudicators may, at their discretion, use the Medical Evidence of Record or the
                     listings suggested to evaluate the claim. However, the decision to allow or deny the
                     claim rests with the adjudicator.
                   |